Latest news : EXACT Therapeutics

06-30	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT
06-26	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial	RE
06-26	EXACT Therapeutics Issues Positive Second Safety Read-Out From Phase 2 ENACT Trial In Pancreatic Cancer	CI
06-17	Euronext Oslo Børs Receives Exact Therapeutics' Delisting Application	MT
05-29	Exact Therapeutics' Board Proposes Delisting from Euronext Growth Oslo	MT
04-09	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	Exact Therapeutics as Doses First Patient in Europe in Phase 2 Enact Trial for Locally Advanced Pancreatic Cancer	CI
01-27	Exact Therapeutics as Announces Positive Initial Safety Read-Out from the Phase 2 Enact Trial in Pancreatic Cancer	CI
11-24	Exact Therapeutics introduces new long-term incentive program	RE
25-09-25	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-25	Exact Therapeutics H1 operating loss widens to NOK 45.9 million	RE
25-08-12	EXACT Therapeutics AS to Present at the European Society for Medical Oncology Congress 2025	CI
25-07-08	Exact Therapeutics announces grant of core patent in U.S.	RE

More news

Press Releases: EXACT Therapeutics

07-02	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares	PU
06-30	EXACT Therapeutics AS - Removal from trading	AQ
06-26	EXACT Therapeutics: Positive second safety read-out from the Phase 2 ENACT trial in pancreatic cancer	PU
06-12	EXACT Therapeutics minutes from Annual General Meeting June 12, 2026	AQ
06-04	EXACT Therapeutics - webcast presentation	AQ

More press releases

Managers and Directors: EXACT Therapeutics

Manager	Title	Age	Since
Per Walday CEO	Chief Executive Officer	66	2022-06-05
Svein Kvåle COO	Chief Operating Officer	-	2011-12-31
John Edminson DFI	Director of Finance/CFO	-	2022-09-30

Director	Title	Age	Since
Masha Paule Nathalie Strømme CHM	Chairman	55	2018-06-21
Anders Wold CHM	Chairman	-	2022-06-07
Ann-Tove Kongsnes BRD	Director/Board Member	59	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT THERAPEUTICS	-4.00%	-10.00%	-74.47%	-94.00%	4.63M
LONZA GROUP AG	+2.14%	+8.75%	+5.16%	+11.05%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+604.02%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.27%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+55.45%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+8.30%	+37.95%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+135.37%	15.92B
EUROFINS SCIENTIFIC SE	+0.98%	+2.73%	+16.19%	+23.96%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+93.88%	13.52B
Average	+1.67%	+4.24%	+62.87%	+95.71%	24.57B
Weighted average by Cap.	+2.20%	+6.53%	+90.91%	+136.78%

See all sector performances

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-02 - Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-07-03	NOK 0.7200	-4.00%	9,022
26-07-02	NOK 0.7500	-5.66%	44,800
26-07-01	NOK 0.7950	-2.45%	14,783
26-06-30	NOK 0.8150	+1.87%	62,920
26-06-29	NOK 0.8000	0.00%	32,000

Real-time Oslo Bors

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Real-time Oslo Bors Other stock markets 10:45:00 2026-07-03 EDT			5-day change	1st Jan Change
0.7200 ^NOK	-4.00%		-10.00%	-47.83%

Market Cap	45.55M 4.63M 4.05M 3.72M 3.47M 6.58M 441M 6.68M 44.68M 17.37M 217M 17.39M 17.02M 747M	P/E 2024	-2.49x	P/E 2025	-1x
Enterprise Value	21.64M 2.2M 1.92M 1.77M 1.65M 3.13M 210M 3.17M 21.23M 8.25M 103M 8.26M 8.08M 355M	EV / Sales 2024	-	EV / Sales 2025	1,074,437,000x
Free-Float	30.97%	Yield 2024 *	-	Yield 2025	-

1 day	-4.00%
1 week	-10.00%
Current month	-11.66%
1 month	-4.64%
3 months	-55.00%
6 months	-49.65%
Current year	-47.83%

1 week	0.67	0.86
1 month	0.58	0.93
Current year	0.58	2.7
1 year	0.58	3
3 years	0.58	20
5 years	0.58	24.8
10 years	0.58	53.59

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-01-03	Masha Paule Nathalie Strømme	Buy	Director	2,500	0.0083%
23-01-03	Anders Wold	Buy	Chairman	2,500	0.0083%
23-01-03	John Edminson	Buy	Chief Financial Officer	2,500	0.0083%

EXACT Therapeutics Stock

Stocks

EXTX

NO0010852213

Biotechnology & Medical Research

Valuation: EXACT Therapeutics

Chart: EXACT Therapeutics

Latest news : EXACT Therapeutics

Press Releases: EXACT Therapeutics

Quotes and Performance

Course Extremes

Managers and Directors: EXACT Therapeutics

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

	2024	2025
Net sales	-	0.06 0.01 0.01 0 0 0.01 0.57 0.01 0.06 0.02 0.28 0.02 0.02 0.97
Net income	-52.33M -5.32M -4.65M -4.28M -3.99M -7.56M -507M -7.67M -51.34M -19.96M -249M -19.98M -19.55M -858M	-86.97M -8.85M -7.73M -7.11M -6.62M -12.56M -842M -12.75M -85.31M -33.16M -414M -33.2M -32.49M -1.43B
Net Debt	-98.89M -10.06M -8.79M -8.08M -7.53M -14.29M -958M -14.5M -97.01M -37.71M -471M -37.75M -36.94M -1.62B	-23.91M -2.43M -2.13M -1.95M -1.82M -3.45M -232M -3.51M -23.46M -9.12M -114M -9.13M -8.93M -392M